Skip to content
Markets

Novavax Lifts Its 2026 Revenue Outlook to as Much as $415m on a $125m Sanofi Milestone

Novavax raised its 2026 revenue guidance to $385m to $415m after a $125m Sanofi milestone, while third-quarter revenue slipped 3% to $68.3m and its net loss narrowed to $31.4m.

The white Novavax headquarters building in Gaithersburg, Maryland, with the Novavax logo on its corner under a blue, cloudy sky.
Photo: Toriino7 / Wikimedia Commons, CC BY 4.0

Novavax has raised its 2026 revenue outlook by $145m at the midpoint, to between $385m and $415m, after earning a $125m milestone from Sanofi in October. Third-quarter revenue slipped 3% to $68.3m, but cost cuts helped narrow the net loss to $31.4m from $202.4m a year earlier.

The Sanofi milestone

The jump in guidance comes almost entirely from the milestone. On 29 October Novavax said Sanofi had dosed the fifth patient in a Phase 3 trial in Europe of a combined flu and Covid vaccine, triggering a $125m payment. The trial tests Novavax's Covid vaccine, Nuvaxovid, given together with Sanofi's high-dose flu vaccine, Efluelda/Fluzone High-Dose, in adults aged 60 and over.

Novavax says the partnership with Sanofi, signed in May 2024, has now brought in more than $1bn, counting upfront payments, milestones, research reimbursements and royalties. Two more milestones are in sight: $75m when the transfer of Nuvaxovid manufacturing technology to Sanofi is completed, expected in mid-2027, and $225m if a combined flu and Covid vaccine is launched in the US. Sanofi intends to start a US Phase 3 trial of the combination in 2027.

Novavax: share price, chart and news

A Novavax scientist in a lab coat, mask and safety glasses works at a laboratory bench at the company's Gaithersburg site.
A Novavax scientist in a lab coat, mask and safety glasses works at a laboratory bench at the company's Gaithersburg site. Photo: Maryland GovPics / Wikimedia Commons, CC BY 2.0

The third quarter

MeasureQ3 2026Q3 2025
Total revenue$68.3m$70.4m
Product sales$25.7m$13.4m
Licensing, royalties and other$42.6m$57.0m
Research and development$52.4m$98.3m
Selling, general and administrative$23.6m$31.7m
Net loss$31.4m$202.4m
Loss per share$0.19$1.25

Product sales almost doubled, but licensing and royalty income fell by a quarter as research reimbursements from Sanofi dropped by $42m. That support for Sanofi's post-approval commitments on Nuvaxovid is nearing its end. The year-earlier loss included a $97.0m impairment on assets held for sale and a $28.7m loss on paying off debt.

Over nine months, revenue fell to $264.5m from $976.3m, and Novavax swung to a net loss of $94.3m from net income of $422.8m.

DAX over the last three months. Exchange data, delayed up to 15 minutes.
DAX over the last three months. Exchange data, delayed up to 15 minutes.

The new guidance

2026 outlook, updated 5 November

  • $385m to $415m adjusted total revenue, up from $235m to $275m
  • $125m Sanofi combination vaccine milestone now included
  • $375m to $395m combined R&D and SG&A spending

Besides the milestone, Novavax nudged up its forecasts for Nuvaxovid product sales to $40m to $50m, for supply sales to $50m to $60m, and for licensing, royalties and other income to $170m to $180m. The adjusted figures leave out commercial supply sold to Sanofi. Combined research and administrative spending is expected to be slightly lower than before.

An updated version of Nuvaxovid, matched to the XFG Covid variant, was approved in the US, the EU and Japan in August. Sanofi and Takeda, Novavax's partner in Japan, have started selling it for the 2026-2027 season, and Novavax is eligible for royalties on their sales.

Chief executive John Jacobs said that over time the partnership strategy could "build a robust and profitable Novavax".

Cash, debt and risks

Novavax ended September with $627m of cash, cash equivalents, marketable securities and restricted cash, down from $751m at the end of 2025. The $125m milestone was earned after the quarter closed. Long-term debt stood at $292.1m, and shareholders' equity was negative at $216.9m.

The company remains loss-making and depends heavily on Sanofi for future payments. A US launch of the combination vaccine, and the $225m that comes with it, depends on Sanofi completing US trials and approvals, which may need more studies than in other markets. Novavax also depends heavily on the Serum Institute of India for co-formulating, filling and finishing its Covid vaccine.

What to watch

  • Fourth-quarter results, the first to include the $125m milestone
  • The start of Sanofi's US Phase 3 combination trial, planned for 2027
  • The $75m technology transfer milestone, expected in mid-2027
  • Royalty income from Sanofi and Takeda over the 2026-2027 season

Sources

Related stories

Investing

Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash

Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to…

Markets

GSK Shares Fall Nearly 5% as Shingrix and Arexvy Miss Forecasts Despite a Profit Beat

GSK shares fell 4.7% to 1,834p after Shingrix and Arexvy vaccine sales missed forecasts by 8% and 16%, overshadowing third-quarter core operating profit of £3.08bn that beat the…

Markets

Redwire Shares Slump 21% as Third-Quarter Revenue Misses Despite Record Margins

Redwire's third-quarter revenue rose only 5.4% to $109m, well below forecasts, sending shares down about 21%, even as gross margin hit a record 32.3% and backlog reached $619.7m.

Markets

NioCorp Developments Books a Paper Profit as Cash Holds Above $400m Before Elk Creek Funding

NioCorp Developments earned $3.76m in its September quarter thanks to $8.5m of non-cash gains as its shares fell. It holds $403.4m of cash, but Elk Creek still needs most of…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.